<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411709</url>
  </required_header>
  <id_info>
    <org_study_id>CRC287</org_study_id>
    <nct_id>NCT01411709</nct_id>
  </id_info>
  <brief_title>A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress</brief_title>
  <official_title>A Pilot Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress Assessed Under Laboratory Conditions And In Everyday Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Surrey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Willmar Schwabe GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Surrey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot investigation into the stress relieving properties of Vitano® which will assess the&#xD;
      following hypotheses&#xD;
&#xD;
      Individuals exposed to Vitano® will demonstrate diminished blood pressure and heart rate&#xD;
      responses to mental stress compared to individuals in the control condition&#xD;
&#xD;
      Physiological recovery (BP, HR and cortisol) from mental stress will be enhanced in&#xD;
      individuals exposed to Vitano® compared to individuals in the control condition&#xD;
&#xD;
      Vitano® will have positive effects on cognitive functioning.&#xD;
&#xD;
      Subjective ratings of stress will be reduced in individuals exposed to Vitano® compared to&#xD;
      individuals in the control condition&#xD;
&#xD;
      There will be a significant improvement in subjective well-being in individuals taking&#xD;
      Vitano®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure measurements</measure>
    <time_frame>Measurements over 14 days (Day 0, Day 7 and Day 14)</time_frame>
    <description>Blood pressure readings taken under laboratory conditions during cognitive testing and relaxation periods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of cognitive function</measure>
    <time_frame>14 days</time_frame>
    <description>cognitive function assessed four times during the 14 day study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Mild Stress/Anxiety</condition>
  <arm_group>
    <arm_group_label>Vitano</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No tablets - control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitano</intervention_name>
    <description>two 200mg tablets per day for 14 days</description>
    <arm_group_label>Vitano</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subject is able to read and understand the Informed Consent Form (ICF), and understand&#xD;
             study procedures.&#xD;
&#xD;
          -  The subject has signed the ICF.&#xD;
&#xD;
          -  Healthy male or female subjects aged 18-35 years inclusive. Attempts will be made to&#xD;
             achieve an equal gender ratio through appropriate screening procedures, but a failure&#xD;
             to do so will not preclude analysis of the final data set.&#xD;
&#xD;
          -  A score above 30 on the Spielberger State-Trait Anxiety Inventory (STAI).&#xD;
&#xD;
          -  The subject agrees to use suitable methods of contraception during the study and for 3&#xD;
             months afterwards.&#xD;
&#xD;
          -  The subject is a non-smoker.&#xD;
&#xD;
          -  The subject is, in the opinion of the Investigator, healthy on the basis of medical&#xD;
             history, vital signs, and the results of routine laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is pregnant or breast feeding.&#xD;
&#xD;
          -  The subject consumes more than 5 caffeine-containing beverages per day.&#xD;
&#xD;
          -  The subject is colour blind.&#xD;
&#xD;
          -  Clinically significant hepatic or renal abnormality as determined by laboratory tests.&#xD;
&#xD;
          -  BMI above 33.&#xD;
&#xD;
          -  History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence&#xD;
             within the 12 months preceding Visit 1.&#xD;
&#xD;
          -  Positive alcohol breath test at any visit. A repeat test will not be allowed. [NOTE:&#xD;
             subjects must be told to avoid consumption of alcoholic beverages for at least 24&#xD;
             hours prior to attending the Centre].&#xD;
&#xD;
          -  Use of any other medication which may interfere with study outcome and/or interfere&#xD;
             with IMP within the 2 weeks or 5 half lives preceding the first treatment phase, with&#xD;
             the exception of contraceptive pill, non-steroidal analgesics, and paracetamol. [NOTE:&#xD;
             Concomitant medications which do not influence study outcome and/or do not interfere&#xD;
             with IMP may be allowed at the discretion of the Investigator].&#xD;
&#xD;
          -  Current participation in another clinical trial with an investigational or&#xD;
             non-investigational drug or device, or participation in another clinical trial within&#xD;
             the 3 months preceding Visit 1 (screening visit).&#xD;
&#xD;
          -  Any condition that, in the Investigator's opinion, compromises the subject's ability&#xD;
             to meet protocol requirements or to complete the study.&#xD;
&#xD;
          -  Moderate or severe anxiety* *If participants are found to have moderate or severe&#xD;
             anxiety during the screening process then they will be referred to the University&#xD;
             Counselling service.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Surrey</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Hubert Bland</name_title>
    <organization>University of Surrey</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

